Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): Last Trade: The Company rose 4.12% and finished at $9.09. The daily volume was measured at 1.63 million shares. The 52-week high of the share price is $14.50 and the 52-week low is …
With its Copaxone and Lovenox generic drugs driving revenues, as well as being a potential takeout candidate, Momenta Pharmaceutical stock should easily hit $25 per share in 2016. Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals …
Biotechnology
The Piper Jaffray price target for the stock is $26, and the consensus target is higher at $31. Repros closed Wednesday at $21.83. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is running radio spots for its non 24 drug, Tasimelteon. New …
Wall Street
Stock-Callers.com reviews the recent performances of the following equities today: ImmunoGen Inc. (NASDAQ: IMGN), …
ImmunoGen, Inc.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) traded 548554 shares and was closed at $14.25 per share. The current share price indicate that stock is -20.83% away from its one year high and is moving 106.23% ahead of its one year …
The stock has "Outperform" rating by Wells Fargo on Wednesday ... last issued …
Partners
The stock was sold at an average price of $23.23 ... Its down 0.50, from 1.47 in 2016Q3. (NASDAQ:VNDA). Swiss Bancshares holds 0% or 63,400 shares in its portfolio. Rice Midstream Partners (NYSE:RMP) last announced its …
Analyst
Vanda Pharmaceuticals Inc’s share price rose by 6.91% in the last 175 days and is still going upwards. Our equity …
“Since then, every time we have seen a minor correction in this stock, it has been met with strong demand and support. I project that the current momentum in VNDA will continue to rise over the next few coming months, and I am looking for …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VNDA at https://www.zacks.com/ap/VNDA
CNBC20d
Vanda